Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients

Canadian Journal of Neurological Sciences

Volumn 28, Issue 4, 2001, Pages 313-318

  Meckling, S K ^a   Becker, W J ^a   Rose, M S ^a   Dalby, J T ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; DYSTHYMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENSTRUATION; MENTAL DISEASE; MIGRAINE; OBSESSION; PANIC; PERSONALITY; PHOBIA; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SEROTONINERGIC SYSTEM; SUBSTANCE ABUSE; VOMITING;

ADULT; FEMALE; HUMANS; MALE; MENSTRUAL CYCLE; MENTAL DISORDERS; MIDDLE AGED; MIGRAINE DISORDERS; NEUROPSYCHOLOGICAL TESTS; PATIENTS; PERSONALITY ASSESSMENT; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0035669536     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100001529     Document Type: Article

References (30)

1. Treatment of acute migraine with subcutaneous sumatriptan
2. Treatment of migraine attacks with sumatriptan
3. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled dose range-finding study
4. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study
5. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
6. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
7. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
8. Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine
9. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo
10. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
11. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan
12. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain
13. Subcutaneous sumatriptan in a clinical setting: The first 100 consecutive patients with acute migraine in a tertiary care center
14. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat
15. Classification of daily and non-daily headaches: Field trial of revised IHS criteria
16. Treatment of oral sumatriptan nonresponders with 5 mg zolmitriptan and 10 mg rizatriptan: A comparative open trial
17. Sumatriptan: An oral dose-defining study
18. Rizatriptan vs sumatriptan in the acute treatment of migraine
19. Sumatriptan in clinical practice: A two year review of 453 migraine patients
20. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response
21. 1B receptor polymorphism and clinical response to sumatriptan
22. Sumatriptan-Nonresponders: A survey in 366 migraine patients
23. The role of estradiol withdrawal in the etiology of menstrual migraine
24. The role of progesterone in menstrual migraine
25. Migraine and psychopathology: Results of the Zurich Cohort study of young adults
26. Comorbidity of migraine and major affecfive disorders
27. 1D receptor function in major depression: A neuropharmacological challenge study using sumatriptan
28. National Institute of Mental Health diagnostic interview schedule
29. Personality